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Abstract
Beyond	their	role	in	hemostasis	and	thrombosis,	platelets	are	increasingly	recognized	
as	key	regulators	of	the	inflammatory	response	under	sterile	and	infectious	conditions.	
Both	platelet	receptors	and	secretion	are	critical	for	these	functions	and	contribute	
to	their	interaction	with	the	endothelium	and	innate	immune	system.	Platelet‐leuko‐
cyte	interactions	are	increased	in	thrombo‐inflammatory	diseases	and	are	sensitive	
biomarkers	 for	 platelet	 activation	 and	 targets	 for	 the	 development	 of	 new	 thera‐
pies.	The	crosstalk	between	platelets	and	innate	immune	cells	promotes	thrombosis,	
inflammation,	 and	 tissue	damage.	However,	 recent	 studies	have	 shown	 that	 these	
interactions	also	 regulate	 the	 resolution	of	 inflammation,	 tissue	 repair,	and	wound	
healing.	Many	of	the	platelet	and	leukocyte	receptors	involved	in	these	bidirectional	
interactions	are	not	 selective	 for	a	 subset	of	 immune	cells.	However,	 specific	het‐
erotypic	interactions	occur	in	different	vascular	beds	and	inflammatory	conditions,	
raising	the	possibility	of	disease‐	and	organ‐specific	pathways	of	intervention.	In	this	
review,	we	highlight	and	discuss	prominent	and	emerging	interrelationships	between	
platelets	and	innate	immune	cells	and	their	dual	role	in	the	regulation	of	the	inflam‐
matory	response	in	sterile	and	infectious	thrombo‐inflammatory	diseases.	A	better	
understanding	of	the	functional	relevance	of	these	interactions	in	different	vascular	
beds	may	provide	opportunities	for	successful	therapeutic	interventions	to	regulate	
the	development,	progression,	and	chronicity	of	various	pathological	processes.
K E Y W O R D S
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Essentials
•	 Platelet‐innate	immune	cell	interactions	regulate	the	development	and	outcome	of	thrombo‐inflammatory	diseases
•	 Platelet	activation	potentiates	innate	immune	cell	recruitment,	activation,	and	transmigration
•	 Platelets	promote	the	progression	and	resolution	of	inflammation	in	a	disease‐specific	manner
•	 Platelet‐leukocyte	interactions	differentially	regulate	thrombo‐inflammation
Handling	Editor:	Cihan	Ay
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1  | INTRODUCTION
Platelets	are	small,	anucleated	cell	fragments	derived	from	megakaryo‐
cytes	and	known	for	their	hemostatic	functions	at	the	site	of	vascular	
lesion.	 In	 the	past	2	decades,	multiple	 roles	 for	platelets	beyond	he‐
mostasis	have	been	shown,	including	in	vascular	permeability,	 inflam‐
mation,	 infection,	 and	 tissue	 repair.1‒5	More	 recently,	 a	 new	 role	 for	
platelets	in	the	maintenance	of	vascular	integrity	at	the	site	of	inflamma‐
tion	was	described,	a	process	currently	termed	inflammatory hemosta-
sis.3,6‒10	Both	hemostatic	and	immunomodulatory	functions	of	platelets	
are	tightly	regulated	by	environmental	cues,	in	particular	their	interac‐
tion	with	the	endothelium	and	innate	immune	system	components.
The	concept	of	thrombo‐inflammation	was	originally	introduced	
to	describe	 the	 role	of	platelets	 in	 the	 inflammatory	 response	 fol‐
lowing	 cerebral	 ischemia‐reperfusion	 injury.11	 It	 is	 currently	more	
broadly	used	to	describe	various	diseases	regulated	by	the	crosstalk	
between	 thrombosis	 and	 inflammation,	 such	 as	 deep	 vein	 throm‐
bosis,	 stroke	 and	 atherosclerosis,	 and	 infectious	 diseases,	 such	 as	
sepsis.	 The	 common	 feature	 in	 thrombo‐inflammatory	 disease	 is	
interplay	of	the	endothelium	and	immune	and	hemostatic	systems.	
In	these	diseases,	inflammation	triggers	thrombosis,	which	in	return	
fuels	the	inflammatory	response.	Increased	platelet‐leukocyte	inter‐
actions	on	the	 inflamed	endothelium,	 in	 thrombi,	and	 in	 the	blood	
are	observed	in	thrombo‐inflammatory	experimental	models	and	in	
patients	 with	 atherosclerosis,	 acute	 coronary	 syndrome,	 ischemic	
stroke,	deep	vein	thrombosis	(DVT),	and	sepsis.12‒17	The	level	of	cir‐
culating	platelet‐leukocyte	aggregates	(PLAs)	is	suggested	to	be	both	
a	sensitive	biomarker	for	platelet	activation	and	a	novel	therapeutic	
target.	 For	 example,	 platelet	 activation	 and	platelet‐monocyte	 ag‐
gregates	in	acute	coronary	syndrome	are	used	as	an	early	hallmark	
for	 acute	myocardial	 infarction.12	 Furthermore,	 platelet‐monocyte	
aggregates	after	myocardial	infarction	are	more	sensitive	markers	of	
platelet	activation	than	P‐selectin.13	However,	it	is	unclear	whether	
these	 interactions	 are	 a	 cause,	 an	active	participant,	 or	merely	 an	
epiphenomenon	 of	 the	 inflammatory	 response.	 In	 this	 review,	we	
focus	on	established	and	emerging	 interactions	between	platelets	
and	innate	immune	cells	and	discuss	the	evidence	that	links	these	in‐
teractions	to	function	in	disease	states	in	different	vascular	beds,	in	
particular	in	the	maintenance	of	vascular	integrity	and	inflammation.
2  | PLATELETS SUPPORT CLASSICAL AND 
INFLAMMATORY HEMOSTASIS
At	the	site	of	vascular	injury	and	under	high	shear	conditions,	plate‐
lets	roll	and	adhere	to	the	exposed	extracellular	matrix	through	gly‐
coprotein	Ib	(GPIb)–von	Willebrand	factor	(VWF)	and	glycoprotein	VI	
(GPVI)–collagen	interactions.	Platelet	activation	leads	to	platelet	inte‐
grin	GPIIbIIIa	activation,	the	release	of	granule	contents	including	the	
feedback	agonist	ADP,	and	the	formation	of	thromboxane	A2	(TxA2),	
promoting	 recruitment	 of	 circulating	 platelets.	While	 the	 formation	
of	a	platelet	plug	supports	classical	hemostasis,	uncontrolled	platelet	
activation	 leads	 to	 pathogenic	 thrombosis.	 Platelet	 granules	 are	 an	
important	source	of	pro‐	and	anti‐inflammatory	mediators,	for	exam‐
ple,	 tumor	 necrosis	 factor‐α	 (TNF‐α);	 transforming	 growth	 factor‐β; 
chemokines,	for	example,	RANTES,	platelet	factor	4	(PF4),	and	neutro‐
phil	activating	peptide	2	(NAP‐2);	endothelial	cell	modulators,	for	ex‐
ample,	sphingosine‐1‐phosphate,	and	serotonin;	and	growth	factors,	
for	example,	platelet‐derived	growth	factor	(PDGF)	and	vascular	en‐
dothelial	growth	factor	(VEGF).18	The	translocation	of	other	proteins	
including	P‐selectin	and	CD40‐ligand	(CD40‐L)	to	the	platelet	surface	
favors	 their	 interactions	with	 immune	and	endothelial	 cells	promot‐
ing	vascular	permeability,	thrombosis,	and	inflammation.19‒21	Platelets	
also	contain	mRNAs	and	pre‐mRNAs	that	are	translated	upon	platelet	
activation,	with	 interleukin	 (IL)‐1β	being	the	most	studied.22	Platelet	
granule	secretion	occurs	instantly	following	platelet	activation,	how‐
ever,	platelet	IL‐1β	is	released	a	few	hours	after	stimulation.
At	 the	 site	 of	 inflammation,	 platelets	 play	 a	 dual	 role	 in	 the	
maintenance	 of	 vascular	 integrity	 and	 inflammation.10	 Platelet	 re‐
cruitment	and	activation	 increase	vascular	permeability,	 leukocyte	
recruitment,	 and	 edema	 through	 the	 release	 of	 chemokines	 and	
permeability	 factors	 with	 key	 roles	 for	 PF4,	 RANTES,	 VEGF,	 and	
serotonin.10,20,23	 However,	 platelets	 also	maintain	 integrity	 of	 the	
endothelial	 cell	 layer	 at	 sites	 of	 endothelial	 damage	 inflicted	 by	
neutrophil	 transmigration,	 thus	 preventing	 inflammatory	 bleed‐
ing.24	 Inflammatory	 hemostasis	 is	 primarily	GPIIbIIIa	 independent,	
although	 in	 certain	 inflammatory	 environments,	 such	 as	 ischemia‐
reperfusion	injury	in	the	brain,	GPIIbIIIa‐dependent	aggregation	can	
be required.3,10	Many	mechanisms	 underlie	 the	 protective	 role	 of	
platelets	in	inflammatory	hemostasis	including	physical	sealing	of	the	
damaged	endothelium	and	secretion	of	soluble	factors	that	tighten	
endothelial	junctions.9	Interestingly,	platelets	adhere	predominantly	
at	the	site	of	endothelial	cell	junctions	during	inflammation	and	guide	
neutrophils	to	their	extravasation	sites.25	Therefore,	the	location	of	
platelet	adhesion	might	be	critical	for	prevention	of	leakage	through	
endothelial	junctions	and	limiting	inflammatory	bleeding.6,7,9	Unlike	
classical	hemostasis,	the	roles	of	platelet	receptors	and	secretion	in	
inflammatory	hemostasis	depend	on	the	vascular	bed	and	the	nature	
of	 the	 inflammatory	 stimulus.7‒9	For	 example,	 platelet	 secretion	 is	
required	to	secure	the	endothelial	barrier	in	the	ischemic	brain	but	
not	in	the	inflamed	skin	or	lung.26	Similarly,	platelet	GPVI	is	required	
to	maintain	vascular	integrity	in	the	inflamed	skin	while	GPIbα	is	re‐
quired	in	the	inflamed	lung.7‒9	Whether	the	difference	is	due	to	the	
nature	and	 intensity	of	 the	 inflammatory	 stimulus,	endothelial	 cell	
heterogeneity,	and/or	the	microenvironment	is	not	known.
Following	injury,	restoration	of	vascular	integrity,	apoptosis,	and	
recruitment	of	progenitor,	stromal	and	immune	cells	are	crucial	for	
tissue	 restructuring,	 remodeling,	 and	 functionality.	 Platelets	 are	
involved	 in	many	 of	 the	 stages	 of	wound	 healing,	 and	 this	 is	 em‐
phasized	by	 the	beneficial	 use	of	 platelet‐rich	 plasma	 and	platelet	
releasate	in	wound	repair.27,28	They	promote	progenitor	cell	recruit‐
ment;	promote	cytokine,	chemokine,	proangiogenic,	and	growth	fac‐
tor	release;	and	support	fibrin	generation	and	modulate	immune	and	
stromal	cell	recruitment	and	activation.29	Platelets	can	also	promote	
the	migration	of	leukocytes	and	stromal	cells	through	the	secretion	
of	metalloproteinase	(MMP)	and	stimulation	of	MMP	secretion	from	
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leukocytes	and	endothelial	 cells,	 promoting	 tissue	 remodeling	and	
repair.28,30	In	addition,	we	have	recently	shown	that	impaired	vascu‐
lar	integrity	due	to	loss	of	platelet	function	can	also	be	beneficial	in	
skin	tissue	repair.	Deletion	of	platelet	C‐type	 lectin‐like	receptor‐2	
(CLEC‐2)	 and	 GPVI	 impairs	 vascular	 integrity	 during	 skin	 wound	
healing	 in	mice	and	results	 in	bleeding	 in	the	tissue.31	The	 leakage	
of	blood	cells	and	plasma	in	the	tissue	accelerates	fibrin	generation,	
inhibits	inflammatory	immune	cell	recruitment,	and	promotes	angio‐
genesis.	It	is	likely	that	the	cause	of	bleeding	and	the	related	pathol‐
ogy	define	the	beneficial	potential	of	safeguarding	vascular	integrity.
3  | PLATELETS PROMOTE LEUKOCYTE 
RECRUITMENT IN INFLAMMATION
Platelets	and	leukocytes	use	a	multistep	pathway	to	accrue	at	the	
site	 of	 inflammation,	 culminating	 in	 integrin	 activation	 and	 firm	
adhesion,	with	 leukocytes	undergoing	 further	migration	 into	 the	
tissue.	The	recruitment	of	leukocytes	to	the	inflamed	endothelium	
is	mainly	observed	 in	 the	postcapillary	venules,	 probably	due	 to	
the	 increased	 density	 of	 cell	 adhesion	molecules	 and	wall	 shear	
rate,	with	a	key	role	for	platelets	 in	 leukocyte	recruitment	in	the	
brain	 venules.32	 The	 interaction	 of	 platelets	 with	 leukocytes	 in	
the	blood	and	at	the	site	of	activated	and	injured	endothelium	in‐
volves	several	 receptor‐ligand	pairs	 including	P‐selectin–P‐selec‐
tin	 glycoprotein	 ligand‐1	 (PSGL‐1),	GPIbα–macrophage	 1	 antigen	
(MAC‐1,	 αMβ2),	 GPIIbIIIa–MAC‐1	 through	 fibrinogen,	 and	 CD40‐
CD40L.21,32‒34	 In	 the	postcapillary	venules,	 platelet	P‐selectin	 is	
required	 for	 platelet	 and	 leukocyte	 recruitment,	 as	 shown	 in	 a	
large	number	of	inflammatory	models.20	The	initial	engagement	of	
P‐selectin–PSGL‐1	induces	rearrangement	of	the	cytoskeleton	of	
leukocytes	and	activation	of	β1‐	and	β2‐integrins,	 leading	to	firm	
adhesion35‒37	(Figure	1).	Platelets	can	also	interact	indirectly	with	
leukocytes	 through	 fibrinogen	 or	 VWF,	 and	 these	 interactions	
F I G U R E  1  Platelets	promote	leukocyte	recruitment,	adhesion,	and	transmigration	at	the	site	of	inflammation	while	maintaining	
vascular	integrity.	Under	inflammatory	challenge,	platelets	are	the	first	cellular	blood	component	adhering	on	the	inflamed	endothelium	
in	small	postcapillary	venules.	Adherent	platelets	recruit	neutrophils	and	guide	them	in	their	adhesion	and	transmigration	through	cell‐
cell	interactions	or	release	of	chemokines	on	the	endothelium.	Activated	platelets	and	neutrophils	cooperate	to	recruit	inflammatory	
monocytes	with	specific	inflammatory	stimuli	such	as	MCP‐1	secretion	required	for	efficient	monocyte	recruitment.	At	the	site	of	leukocyte	
transmigration,	platelets	secure	endothelial	cell	integrity	to	limit	inflammatory	bleeding.	During	inflammation,	platelets	promote	the	
differentiation	of	monocytes	into	macrophages.	Platelet	receptors	or	releasate	can	shift	macrophages	towards	a	pro‐	or	anti‐inflammatory	
phenotype.	CLEC‐2,	C‐type	lectin‐like	receptor‐2;	GPVI,	glycoprotein	VI;	IL‐1,	interleukin‐1;	GPIb,	glycoprotein	Ib;	HMGB‐1,	high‐mobility	
group	box	1;	MAC‐1,	macrophage	1	antigen;	NAP‐2,	neutrophil	activating	peptide	2;	PAF,	platelet‐activating	factor;	PF4,	platelet	factor	4;	
PSGL‐1,	P‐selectin	glycoprotein	ligand‐1;	;	TREM‐1,	triggering	receptor‐expressed	myeloid	cells	1
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differentially	 regulate	 leukocyte	 recruitment	 and	 activation.38,39 
Under	specific	inflammatory	challenges,	such	as	ischemia	and	rep‐
erfusion	injury,	or	injection	of	inflammatory	molecules,	such	as	an‐
giotensin	 II,	P‐selectin,	and	β2‐dependent	 leukocyte	adhesion,	 is	
also	observed	in	arterioles.40,41	Although	the	major	receptors	and	
ligands	have	been	intensively	investigated,	the	implication	of	het‐
erotypic	 cell‐cell	 interactions	 in	 different	 inflammatory	 contexts	
and	organs	are	not	well	known.
Platelet‐mediated	 leukocyte	 recruitment	 is	 also	 potentiated	
through	the	activation	of	the	complement	system.	Platelets	express	
a	large	array	of	complement	receptors	such	as	cC1qR,	gC1qR,	C3aR,	
and	C5aR	and	store	complement	proteins	and	regulators	 including	
C3	and	factor	H,	respectively.	Stimulated	platelets	activate	the	clas‐
sical	and	alternative	pathways	of	complement,	leading	to	the	deposi‐
tion	of	opsonin	C3b	and	the	release	of	anaphylatoxins	C3a	and	C5a,	
potent	 chemoattractants	 for	 innate	 immune	 cells.42,43	 In	 addition,	
platelet‐mediated	complement	activation	promotes	endothelial	cell	
activation,	upregulation	of	tissue	factor,	and	release	of	inflammatory	
cytokines	and	chemokines,	 increasing	 leukocyte	 recruitment,	 acti‐
vation,	and	thrombosis.
Several	 studies	 have	 shown	 the	 importance	 of	 platelets	 in	
neutrophil	 recruitment	 under	 inflammatory	 conditions	 including	
ischemia	 and	 reperfusion	 injury,44	DVT,45,46	 acute	 lung	 injury,	 47 
atherosclerosis,48	 or	 abdominal	 sepsis.49	 Following	 an	 inflamma‐
tory	 insult,	neutrophils	are	rapidly	mobilized	from	the	bone	mar‐
row	to	the	inflamed	tissue	in	response	to	gradients	of	chemokines,	
complement	 components,	 inflammatory	 mediators,	 or	 microbial	
products.50	The	 initial	 interaction	of	P‐selectin	on	platelets	with	
PSGL‐1	 clusters	on	 the	neutrophil	 uropod	plays	 a	 central	 role	 in	
neutrophil	recruitment,	activation	of	MAC‐1	and	αLβ2	(LFA‐1),	and	
formation	of	neutrophil	extracellular	traps	(NETs).51,52 The activa‐
tion	of	MAC‐1	also	allows	the	direct	binding	of	platelets	through	
GPIb‐α	 and	 indirectly	 to	GPIIbIIIa	 through	 fibrinogen,	 increasing	
neutrophil	 adhesion	 and	 transmigration.33,53	 These	 interactions	
physically	tighten	the	bridge	between	neutrophils	and	endothelial	
cells	 and	 induce	 downstream	 signaling	 in	 neutrophils	 promoting	
their	adhesion,	crawling,	and	transmigration.25,54	Platelet‐depen‐
dent	neutrophil	recruitment	is	further	amplified	by	the	secretion	
of	 inflammatory	 cytokines,	 chemokines,	 and	 growth	 factors,	
such	 as	 PF4,	 IL‐1,	 RANTES,	 β‐thromboglobulin,	 PDGF,	 platelet‐
activating	 factor,	 CXCL7,	 migration	 inhibiting	 factor	 (MIF),	 TxA2 
and	 serotonin,	 promoting	 endothelial	 cell	 activation,	 neutrophil	
recruitment,	 adhesion,	 and	 survival55‒59	 (Figure	 1).	 Interestingly,	
single	 adherent	 platelets	 can	promote	 the	 recruitment	 and	non‐
directional	 crawling	 of	 neutrophils.	 However,	 platelet	 secretion	
of	NAP‐2	within	thrombi	generates	a	chemotaxis	gradient	to	pro‐
mote	 leukocyte	directional	migration	through	the	thrombi	 in	 the	
veins.19	Some	of	these	 interactions	occur	 in	many	vascular	beds,	
but	 organ‐specific	 interactions	 also	 occur	 and	 contribute	 to	 the	
immunomodulatory	 functions	 of	 platelets	 and	 to	 inflammatory	
hemostasis.
During	 acute	 inflammation,	monocyte	 release	 from	 the	bone	
marrow	 is	delayed	compared	 to	neutrophils,	but	 they	persist	 for	
longer	 and	 can	 infiltrate	 tissues	 and	 differentiate	 into	 macro‐
phages.60	Neutrophils	and	monocytes	share	common	phagocytic	
and	inflammatory	features;	however,	they	differ	in	their	chemotac‐
tic	stimuli	and	receptors,	release	kinetics	from	the	bone	marrow,	
metabolic	burst	activity,	and	their	interaction	with	the	hemostatic	
system.61	Similar	to	neutrophils,	monocyte	recruitment	to	the	ves‐
sel	 wall	 and	 their	 interaction	 with	 platelets	 involves	 P‐selectin,	
GPIb‐α,	CD40L,	and	GPIIbIIIa.21	Platelets	and	neutrophils	cooper‐
ate	to	promote	subsequent	stable	inflammatory	monocyte	recruit‐
ment.25	Platelet‐mediated	monocyte	recruitment	requires	specific	
inflammatory	stimuli	such	as	monocyte	chemoattractant	protein	1	
(MCP‐1),	which	induces	efficient	monocyte	recruitment	in	the	in‐
flamed	small	postcapillary	venules.25	Monocyte	stable	adhesion	to	
the	inflamed	endothelium	is	further	supported	by	platelet‐derived	
molecules,	 such	as	PF4,	RANTES,	and	MIF,	and	also	chemokines	
secreted	from	the	vessel	wall,	such	as	MCP‐1.62‒64	Therefore,	the	
initial	 attachment	of	neutrophils	and	monocytes	 to	 the	 inflamed	
endothelium	might	not	be	selective,	but	 some	specificity	can	be	
acquired	through	 interaction	with	chemokine	receptors	and	pro‐
teins	selectively	expressed	on	leukocytes	and	on	the	endothelium	
of	different	vascular	beds.21
4  | PLATELET‐LEUKOCYTE INTERACTIONS 
DRIVE THROMBOSIS AND INFLAMMATION
Platelet‐immune	 cell	 interactions	 are	 critical	 for	 limiting	 pathogen	
growth	 and	 dissemination.	 However,	 uncontrolled	 activation	 and	
recruitment	 lead	 to	 thrombosis,	 tissue	 damage,	 and	 loss	 of	 organ	
function.	Activated	platelets	also	 induce	apoptosis	of	 immune	and	
stromal	 cells	 in	 many	 thrombo‐inflammatory	 diseases	 including	
stroke	and	sepsis.	In	mouse	models	of	stroke	and	retinal	inflamma‐
tion,	activated	platelets	induce	apoptosis	in	primary	murine	neuronal	
cells,	human	neuroblastoma	cells,	and	mouse	embryonic	fibroblasts	
via	 membrane‐bound	 Fas	 ligand.65	 This	 form	 of	 nonimmunogenic	
cell	death	 is	required	for	organ	remodeling	and	to	 limit	chronic	 in‐
flammation.	However,	during	sepsis,	the	induction	of	the	expression	
of	apoptotic	molecules	such	as	granzyme	B	due	to	alteration	in	both	
platelet	and	megakaryocyte	mRNA	profiles	increases	lymphotoxic‐
ity	 in	 splenocytes	 and	apoptosis	 in	multiple	organs	 and	decreases	
survival	 rate.66	 This	 shows	 that	 similar	 mechanisms	 differentially	
regulate	thrombo‐inflammation	and	disease‐specific	targeting	is	re‐
quired	for	successful	treatment.
4.1 | Platelet‐neutrophil interaction
Neutrophils	confer	immune	protection	during	infection	through	the	
secretion	of	antimicrobial	proteins,	such	as	defensins,	elastase,	and	
myeloperoxidase;	the	release	of	NETs;	reactive	oxygen	species	(ROS)	
generation;	and	pathogen	phagocytosis.67	Neutrophil	activation	also	
induces	inflammation‐mediated	thrombosis	through	different	path‐
ways	 including	 the	upregulation	of	 tissue	 factor,	NETosis,	 and	 the	
release	of	cathepsin	G	and	elastase,	and	supports	thrombus	stability	
     |  27RAYES Et Al
through	 the	 interaction	 of	 GPIb‐α	 and	 MAC‐1,	 or	 CD40L.45,68‒74 
MAC‐1	interacts	with	adherent	platelets	through	GPIb‐α	mediating	
firm	adhesion	of	leukocytes.	Furthermore,	this	interaction	supports	
thrombosis	as	evidenced	by	a	delay	in	thrombus	formation	after	ca‐
rotid	and	mesenteric	injury	in	MAC‐1	deficient	mice	or	by	blocking	
MAC‐1–GPIb	interaction.72,73	The	MAC‐1–GPIbα	and	shear‐depend‐
ent	MAC‐1	 interaction	with	 fibrinogen	promotes	neutrophil	 adhe‐
sion,	transmigration,	and	thrombus	formation,	with	platelet‐derived	
protein	 disulfide	 isomerase	 reducing	 the	 allosteric	 disulfide	 bonds	
in	GPIbα	and	 increasing	platelet–neutrophil	 interaction.34,38,73,75‒77 
CD40L	 (soluble	 or	 membrane	 bound)	 upregulated	 on	 activated	
platelets	interacts	with	CD40	on	immune	cells	and	promotes	throm‐
bosis	and	 inflammation.72,74	Moreover,	 the	 interaction	with	adher‐
ent	platelets	increases	the	activation	of	neutrophils	by	IL‐8,	c5a,	and	
other	agonists	and	supports	formation	of	homotypic	highly	embolic	
aggregates.78,79	P‐selectin	and	CD40L	also	contribute	to	thrombosis,	
as	shown	by	alteration	in	thrombus	formation	and	stability	by	inhib‐
iting	P‐selectin	or	CD40L,	respectively.74,80
Platelet	interaction	with	neutrophils	boosts	their	immune	func‐
tions	by	increasing	ROS	generation,	phagocytosis,	and	NET	forma‐
tion34,81	 (Figure	 2).	 The	 interaction	 of	 activated	 neutrophils	 with	
platelets	increases	the	release	of	sCD40L,	leading	to	both	increased	
ROS	generation	 in	platelets	and	neutrophils	via	2	 independent	 re‐
ceptors,	 CD40	 and	 GPIIbIIIa.74	 In	 return,	 ROS	 and	 NETs	 support	
platelet‐neutrophil	 interaction,	platelet	activation,	and	vascular	 in‐
flammation.	Platelets	 also	 express	 receptors	 that	 are	not	 required	
for	 platelet‐neutrophil	 interactions	 but	 regulate	 neutrophil	 activa‐
tion.	 For	 example,	 the	 triggering	 receptor‐expressed	myeloid	 cells	
1	 ligand	on	platelets	 increases	neutrophil	 effector	 functions	with‐
out	 altering	 platelet	 neutrophil	 complexes.82	 More	 recently,	 the	
platelet	 immunoreceptor	 tyrosine‐based	 activation	 motif	 (ITAM)	
receptors	CLEC‐2	and	GPVI	have	been	shown	to	regulate	platelet	in‐
teraction	with	neutrophils	during	infection	and	inflammation.3,83‒86 
GPVI	 promotes	 platelet‐neutrophil	 interaction	 during	 pneumonia	
and	 increases	 host	 defense.87	However,	 recent	 evidence	 suggests	
that	platelet‐neutrophil	interaction	can	also	promote	the	resolution	
F I G U R E  2  Platelet‐innate	immune	cell	interactions	modulate	thrombo‐inflammation.	Platelets	interact	with	neutrophils,	monocytes,	
and	macrophages	and	modulate	their	effector	functions.	These	interactions	promote	inflammation	and	thrombosis	through	different	
mechanisms	which	regulate	the	development	and	progression	of	thrombo‐inflammatory	diseases.	NETs,	neutrophil	extracellular	traps;	ROS,	
reactive	oxygen	species;	TF,	tissue	factor
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of	 inflammation	through	the	secretion	of	prorepair	molecules.	The	
protective	role	of	platelet‐neutrophil	interaction	was	shown	in	mu‐
rine	models	 of	 acute	 respiratory	 distress	 syndrome	 and	 postisch‐
emia	reperfusion	injury	in	the	mesenteric	artery	through	the	release	
of	proresolution	mediators	such	as	maresin‐1	and	lipoxin	A4,	respec‐
tively.88,89	These	studies	show	that	platelets	exert	both	protective	
and	detrimental	roles	in	thrombo‐inflammation,	and	it	 is	 likely	that	
the	balance	between	proinflammation	and	proresolution	functions	is	
highly	dependent	on	the	stage	and	the	nature	of	the	disease	as	well	
as	the	microenvironment	(Figure	3).
4.2 | Platelet‐monocyte/macrophage interactions
Platelets	 were	 also	 shown	 to	 modulate	 the	 effector	 functions	 of	
monocytes	by	 inducing	 the	activation	of	 the	nuclear	 factor	kappa‐
light‐chain	 enhancer	 of	 activated	 B	 cells	 (NF‐κb)	 and	 cyclooxyge‐
nase‐2	and	the	synthesis	of	inflammatory	mediators,	such	as	IL‐8	and	
MCP‐161	(Figure	2).	Thrombin‐activated	platelets	bind	to	monocytes	
through	P‐selectin–PSGL‐1	axis.	Blocking	P‐selectin‐PSGL1	interac‐
tion	 however	 does	 not	 inhibit	 platelet‐mediated	 early	 Ca2+ mobili‐
zation	 in	monocytes	 and	 their	 inflammatory	phenotype	 suggesting	
distinct	functions	of	P‐selectin‐PSGL1	in	monocyte	recruitment	and	
activation.90	It	is	possible	that	early	platelet‐mediated	monocyte	acti‐
vation	does	not	require	monocyte	attachment	to	platelets	but	is	cru‐
cial	for	sustained	activation.	Indeed,	enhanced	chemokine	synthesis	
requires	P‐selectin–PSGL‐1	interaction	for	subsequent	activation	by	
RANTES.91	 Platelet‐derived	 high‐mobility	 group	 box	 1	 (HMGB‐1)	
promotes	human	and	mouse	monocyte	recruitment	through	recep‐
tor	for	advanced	glycation	end	products	 (RAGE)	and	 inhibits	apop‐
tosis	 through	 toll‐like	 receptor	 4	 (TLR‐4).92	 These	 interactions	 also	
promote	thrombosis	through	the	release	and	accumulation	of	mono‐
cytes‐derived	tissue	factor‐bearing	microparticles	leading	to	a	proin‐
flammatory	and	prothrombotic	phenotype	in	mice.93
Human	 collagen‐activated	 platelets	 were	 also	 shown	 to	 exert	
anti‐inflammatory	 functions	 on	 human	 monocytes	 by	 increasing	
the	anti‐inflammatory	cytokine	IL‐10	and	reducing	TNF‐α in the ab‐
sence	of	stimuli	partly	through	the	secretion	of	prostaglandin	E2.94 
Activated	 platelets	 also	 promote	 an	 anti‐inflammatory	 phenotype	
and	IL‐10	production	in	human	monocytes	in	presence	of	inflamma‐
tory	 stimuli	 (eg,	 high‐dose	 lipopolysaccharide	 [LPS],	 human	 thyro‐
globulin,	 intact	 Porphyromonas gingivalis).95	 The	 anti‐inflammatory	
effect	of	activated	platelets	is	mediated	by	platelet	secretion,	in	par‐
ticular	CD40‐L	 as	 blocking	CD40L	using	 selective	 antibody	 coun‐
teracts	 the	 effect	 of	 platelets.95	 Activated	 platelets	 differentially	
regulate	the	expression	on	monocyte	cytokines	and	chemokines	and	
their	subsequent	functions	in	inflammation.
During	 acute	 and	 chronic	 inflammation,	 platelets	 promote	
monocyte	 survival	 and	 differentiation	 into	 macrophages,	 partly	
through	the	secretion	of	chemokines	such	as	CXCL‐12	and	PF4.96,97 
In	 human	 monocyte‐derived	 macrophages,	 activated	 platelets	
promote	 LPS‐mediated	 inflammatory	 cytokine	 release	 (high‐dose	
LPS),	which	is	largely	dependent	on	platelet	secretion.98	Using	mice	
bone	 marrow–derived	 macrophages	 in	 vitro,	 activated	 platelets	
induces	 IL‐10	 secretion	 from	 noninflamed	 macrophages	 and	 de‐
creases	 TNF‐α	 release.94	 At	 low	 doses	 of	 LPS,	 platelets	 promote	
TNF‐α	secretion	from	macrophages	but	inhibit	macrophage‐depen‐
dent	 inflammation	at	a	high	dose	of	LPS	and	during	experimental	
bacterial	peritonitis.99	How	platelets	sense	the	intensity	of	the	in‐
flammatory	signal	to	regulate	their	immune	functions	is	not	known.	
Moreover,	 activated	 platelet	 enhances	macrophage	 phagocytosis	
of	 Staphylococcus aureus	 (S aureus)	 independently	 of	 cell	 contact	
through	 the	 release	 of	 IL‐1β,	 increasing	 antimicrobial	 function	 of	
macrophages	and	protection	against	S aureus	infection.100	In	vitro,	
the	 anti‐inflammatory	 effect	 of	 platelets	 in	 the	 presence	 of	 high	
dose	of	LPS	is	independent	of	platelet	secretion,	suggesting	a	key	
role	for	membrane	receptors.	We	have	recently	shown	that	plate‐
let	ITAM	receptor	CLEC‐2	is	a	key	regulator	of	macrophage	activa‐
tion	and	recruitment	in	a	mouse	model	of	acute	respiratory	distress	
syndrome	and	polymicrobial	peritonitis.83,86	The	protective	role	of	
CLEC‐2	is	dependent	on	its	interaction	with	podoplanin	upregulated	
on	inflammatory	macrophages.	Moreover,	GPIb‐CD11b	interaction	
was	also	shown	to	polarize	monocytes	toward	a	proinflammatory	
phenotype	and	to	promote	inducible	nitric	oxide	synthase–positive	
macrophage	recruitment	to	the	infected	peritoneum	and	increases	
bacterial clearance.101	 How	 platelets	 exert	 both	 a	 pro‐	 and	 anti‐
inflammatory	 phenotype	 is	 not	 fully	 known.	 Differential	 platelet	
secretion	might	be	related	to	these	roles,	although	a	single	protein	
can	promote	pro‐	and	anti‐inflammatory	roles	in	different	cells.	For	
example,	serotonin	upregulates	NF‐κB	activation	in	monocytes102 
but	 polarize	 macrophages	 toward	 an	 anti‐inflammatory	 pheno‐
type.103	 Recently,	 injection	 of	 immune	 complexes	 in	 transgenic	
FcγRIIA	mice	was	shown	to	mediate	platelet	activation	and	the	re‐
lease	of	serotonin	leading	to	neutrophil	activation–dependent	ana‐
phylactic	shock.104	These	studies	show	the	bidirectional	beneficial	
or	detrimental	roles	for	platelet‐leukocyte	interactions,	making	this	
another	example	of	tissue‐,	stimuli‐,	and	timing‐dependent	regula‐
tory	functions	for	these	interactions.
5  | THE RELEVANCE OF PLATELET‐
LEUKOCYTE INTERACTIONS IN THROMBO‐
INFLAMMATORY DISEASES
The	 contribution	of	platelet‐leukocyte	 interactions	 to	 thrombo‐in‐
flammation	has	been	extensively	studied	in	the	last	decade	with	rec‐
ognition	that	the	underlying	mechanisms	are	tissue/organ	specific.	
Below,	we	illustrate	some	known	roles	of	these	interactions	in	dif‐
ferent	vascular	beds	and	in	response	to	different	insults,	and	discuss	
the	involvement	of	both	common	and	disease‐specific	pathways	in	
regulation	of	thrombo‐inflammation.
6  | ATHEROSCLEROSIS
Atherosclerosis	 is	 a	 thrombo‐inflammatory	 disorder	 involving	 in‐
flammatory	 and	 immune	 responses	 to	 oxidized	 lipids,	 endothelial	
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dysfunction,	and	the	formation	of	an	atherosclerotic	plaque.	At	the	
site	of	atherosclerosis,	leukocytes	and	platelets	accumulate	and	pro‐
mote	plaque	growth	and	progression	and	eventually	destabilize	the	
endothelial	 layer	 leading	to	plaque	rupture.105‒108	Platelet	and	 leu‐
kocyte	 recruitment	promote	 atherosclerosis	 as	depletion	of	plate‐
lets,	neutrophils	or	monocytes	reduces	plaque	size.106‒108	In	severe	
atherosclerosis,	platelet	recruitment	and	adhesion	preceded	the	de‐
velopment	of	atherosclerotic	lesions	followed	by	leukocyte	recruit‐
ment	 to	 the	arterial	vasculature.106	On	the	 intact	plaque,	platelets	
are	 recruited	 through	GPVI‐laminin	 interaction	 promoting	 athero‐
progression.109	At	the	site	of	fissured	lesions,	plaque	rupture	triggers	
platelet	recruitment	through	GPVI‐collagen	interaction.	Inhibition	of	
GPVI	extracellular	domain	or	downstream	signaling	inhibits	throm‐
bus	formation	on	atherosclerotic	plaque	in	vitro.110,111
Platelet	 activation	 significantly	 contributes	 to	 the	 pathogen‐
esis	 of	 atherosclerosis	 and	 chronic	 vascular	 inflammation,	 in‐
dependently	 of	 atherothrombosis.	 They	 promote	 the	 uptake	 of	
oxidized	 low‐density	 lipoproteins	 (OxLDLs)	 by	 monocytes	 and	
macrophages,112	 increase	monocyte	recruitment	and	adhesion	to	
the	inflamed	or	atherosclerotic	endothelium,48	and	secrete	cyto‐
kines	 and	 chemokines,	 increasing	 plaque	 and	 possibly	 systemic	
inflammation.	Activated	platelets	promote	monocyte	recruitment	
directly	 through	 the	 interaction	 of	 P‐selectin	 with	 PSGL‐1	 and	
CD40L–MAC‐1	and	indirectly	through	the	deposition	of	PF4	and	
RANTES	on	 endothelial	 cells	 and	monocytes	 or	 delivered	 in	mi‐
croparticles.48,113‒117	Moreover,	PF4	was	shown	to	downregulate	
atheroprotective	 genes	 in	 human	 macrophages	 and	 to	 increase	
OxLDL	 uptake	 by	 macrophages,	 exacerbating	 atherosclero‐
sis.118,119	Platelet	PF4	 forms	heteromers	with	RANTES,	 resulting	
in	increased	monocyte	adhesion	to	endothelial	cells	and	disruption	
of	this	interaction	inhibits	atherosclerotic	plaque	formation	in	hy‐
perlipidemic	mice	and	in	a	mouse	model	of	stroke.120,121	Moreover,	
platelet‐dependent	 monocyte	 recruitment	 and	 activation	 may	
increase	 plaque	 instability,	 partly	 by	 promoting	 matrix	 metallo‐
peptidase	9	production	by	monocytes.122	Platelet	activation	and	
secretion	might	also	 increase	endothelial	permeability	and	facili‐
tate	the	accumulation	of	lipids	within	the	vessel	wall.
PLAs,	 and	 in	 particular	 platelet‐monocyte	 aggregates,	 are	 in‐
creased	 in	 patients	 with	 atherosclerotic	 vascular	 disease.17 The 
elevated	 number	 of	 circulating	 PLAs	 increases	 the	 risk	 of	 devel‐
opment	of	 cardiovascular	 and	cerebrovascular	diseases	 associated	
with	 increased	 endothelium	 activation,	 suggesting	 a	 proinflamma‐
tory	role	of	PLAs	in	atherosclerosis.17	Due	to	the	role	of	platelets	in	
inflammation	and	thrombosis,	classical	antiplatelet	drugs	are	used	to	
treat	 thrombotic	 events	 in	 arterial	 cerebrovascular	 and	 cardiovas‐
cular	thrombosis	including	atherosclerosis.21,123	In	particular,	P2Y12 
inhibitors	 have	 additional	 anti‐inflammatory	 properties	 associated	
with	 a	 decrease	 in	 platelet	 P‐selectin,	 PLAs,	 and	 soluble	 CD40L	
and	RANTES.17	Despite	 the	 antithrombotic	 and	 anti‐inflammatory	
effects,	these	drugs	do	not	prevent	the	progression	of	established	
atherosclerosis	 in	 patients.	 More	 recently,	 other	 therapies	 that	
disrupt	 PLAs	 were	 developed,	 including	 inhibitors	 of	 P‐selectin,	
PSGL‐1,	CD40L,	and	GPIb	and	their	beneficial	or	harmful	outcome	in	
atherosclerosis	was	recently	reviewed.21	While	some	of	these	inhib‐
itors	showed	promising	results	in	experimental	models,	results	from	
some	clinical	trials	have	been	disappointing	while	others	are	still	on‐
going.	Moreover,	the	role	of	membrane	receptors	and	soluble	media‐
tors	might	require	combined	therapies	to	improve	clinical	outcomes.	
The	heterogeneity	of	 the	disease	and	 the	engagement	of	multiple	
receptors	 throughout	 disease	 progression	 might	 account	 for	 the	
differences	observed	between	patients	and	experimental	models.21 
Therefore,	the	use	of	biomarkers	for	different	disease	stages	might	
increase	the	possibility	of	selective	drug	targeting,	with	reduced	side	
effects.
7  | DEEP VEIN THROMBOSIS
DVT	is	a	multifactorial	disease,	in	which	the	reduction	of	blood	flow,	
hypoxia,	 and	 endothelial	 and	 stromal	 cell	 activation	 contribute	 to	
thrombus	development	in	veins.	DVT	is	most	commonly	developed	
in	the	 legs	under	the	muscular	fascia	of	the	 limbs	or	 in	the	central	
deep	 veins.	 DVT	 causes	 and	 pathogenesis	 may	 differ	 depending	
on	genetic	and	environmental	 factors.	 It	 is	 important	 to	note	 that	
the	location	and	stability	of	the	thrombi	rather	than	thrombus	size	
is	 associated	 with	 worse	 outcome	 due	 to	 the	 life‐threatening	 in‐
creased	 risk	 in	 pulmonary	 embolism.124,125	Moreover,	 the	 damage	
inflicted	 to	 the	 vessel	 wall	 promotes	 a	 postthrombotic	 syndrome	
and	increases	the	risk	of	recurrent	DVT.	During	experimental	DVT	
in	mice	triggered	by	the	ligation	of	the	inferior	vena	cava,	platelets,	
and	leukocytes	are	recruited	to	the	vascular	wall	preceding	throm‐
bus	formation.46,126	Platelets	are	recruited	as	single	cells	or	small	ag‐
gregates,	directly	binding	to	the	vessel	wall	and	forming	heterotypic	
aggregates	with	leukocytes	via	GPIbα.	Whereas	monocytes	support	
DVT	predominantly	by	providing	tissue	factor,	which	triggers	blood	
coagulation,	neutrophils	promote	thrombosis	by	releasing	NETs.127 
The	factor	triggering	NETosis	 in	the	sterile	environment	inside	the	
blood	vessel	has	been	proposed	to	be	platelet‐derived	HMGB‐1.	The	
effect	of	HMGB‐1	is	potentiated	via	the	P‐selectin–PSGL‐1	axis,128 
with	P‐selectin–deficient	mice	being	protected	against	DVT.46,129,130 
In	addition	to	promoting	NETosis,	platelet‐originated	HMGB‐1	also	
increases	 neutrophil	 and	 monocyte	 sequestration	 at	 the	 venous	
wall,	 increasing	local	 inflammation.	More	recently,	complement	ac‐
tivation	was	 shown	 to	 regulate	 the	 development	 of	DVT	 in	mice,	
with	 complement	 components	 displaying	 distinct	 roles	 in	 throm‐
bus	formation.	C3	activation	leads	to	platelet	and	fibrin	deposition,	
whereas	C5	 increases	 tissue	 factor	 expression	 on	monocytes	 and	
precipitates	fibrin	generation,	independently	of	platelets,	promoting	
thrombo‐inflammation.131
An	increase	in	PLAs	is	observed	in	patients	with	venous	throm‐
bosis.16	 In	particular,	 the	 increase	 in	 circulating	platelet‐neutrophil	
aggregates	has	been	shown	to	correlate	with	platelet	activation	 in	
individuals	with	DVT,132	 with	 the	 ROC	 revealing	 that	 the	 level	 of	
platelet‐neutrophil	 aggregates	 represents	 a	 risk	 factor	 for	 venous	
thrombosis.	Platelet‐monocyte	aggregates	are	also	 increased	after	
surgery	in	patients	with	venous	thromboembolism	(VTE),	and	their	
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count	correlates	with	plasma	levels	of	an	important	systemic	proin‐
flammatory	marker,	C‐reactive	protein.133
Anticoagulants	are	the	common	mainstay	of	treatment	of	DVT,	
although	thrombolysis,	mechanical	thrombectomy,	and	angioplasty	
are	also	used.	Antiplatelet	drugs,	 in	particular	aspirin,	were	shown	
to	reduce	the	risk	of	primary	thromboembolism	and	the	recurrence	
of	 secondary	 VTE	 when	 used	 as	 a	 long‐term	 secondary	 preven‐
tive	strategy	in	patients	with	VTE	following	an	initial	anticoagulant	
treatment.134‒136
Thus,	although	the	activation	of	 the	coagulation	system	drives	
venous	thrombosis,	the	interaction	of	platelets	with	innate	immune	
cells,	both	in	the	flowing	blood	and	at	the	vessel	wall,	directly	con‐
tribute	to	the	initiation	and	progression	of	DVT	and	the	associated	
inflammatory	response.
8  | SEPSIS
Platelets	express	a	wide	range	of	complement	receptors,	pattern	
recognition	 receptors,	 in	 particular	 toll‐like	 receptors	 and	Fc	 re‐
ceptors,	providing	the	ability	to	sense	and	respond	to	endogenous	
and	exogenous	inflammatory	and	infectious	signals	and	initiate	an	
immune	response.137	Following	activation,	platelets	secrete	a	large	
array	of	antimicrobial	and	immunomodulatory	molecules	that	can	
directly	kill	pathogens	and/or	enhance	immune	cell	differentiation	
and	 activation.	 Platelet	 depletion	 and	 thrombocytopenia	 are	 as‐
sociated	with	worse	outcome,	suggesting	their	protective	role	 in	
sepsis.85,138	In	mouse	models	of	bacterial	peritonitis,	early	platelet	
transfusion	 is	 protective	 through	 the	 regulation	 of	 macrophage	
activation.99,101	 Platelet	 transfusion	 attenuates	 thrombocytope‐
nia,	 decreases	 plasma	 levels	 of	 inflammatory	 cytokines	 such	 as	
TNF‐α	and	IL‐6,	and	improves	survival.99	Platelet	transfusion	was	
also	shown	to	 increase	 inflammatory	macrophage	recruitment	to	
the	infected	peritoneum	and	improve	bacterial	clearance	through	
GPIb‐CD11b	interaction.101	It	is	possible	that	platelet	transfusion	
dampens	the	systemic	 inflammatory	response	partly	through	se‐
questration	of	cytokines	released	from	activated	immune	cells	and	
the	regulation	of	immune	cell	activation.83,85,86,101
During	 sepsis,	 platelets	 contribute	 to	 leukocyte	 recruitment	
and	 activation	 through	both	 direct	 interaction	 and	 via	 secretion	
supporting	 immune	 cell	 recruitment	 and	 pathogen	 clearance,	
with	 an	 organ	 and	 pathogen	 role	 for	 platelet	 receptors	 and	 se‐
cretion.139,140	 Deficiency	 in	 these	 interactions	 reduces	 PLAs	 in	
bacterial	 sepsis	 and	 increases	 bacterial	 growth	 in	 an	organ‐	 and	
insult‐dependent	 manner.85,87,139,141,142	 Interestingly,	 the	 protec‐
tive	 role	of	platelet	 receptors	depends	on	 the	pathogen	and	 the	
site	 of	 infection.	 Following	 gram‐negative	 bacterial	 infection	 in	
mice,	LPS	binding	to	TLR4	on	platelets	induces	NET	release	from	
neutrophils	and	sequesters	bacteria	within	the	vasculature,	in	par‐
ticular	in	pulmonary	capillaries	and	liver	sinusoid.143	NET	release	
is	 also	 induced	 by	 P‐selectin,128,	 platelet	 release	 of	HMGB‐1,144 
β1‐defensins,145	and	other	interactions.	Moreover,	LPS	binding	to	
TLR4	on	platelets	induce	the	shedding	of	IL‐1β	rich	microparticles	
increasing	endothelial	cell	activation	and	propagating	the	inflam‐
matory	response.146	Platelets	and	NETs	also	induce	disseminated	
intravascular	 coagulation	 and	 alter	 organ	 functions.147	 Targeting	
NETs	in	sepsis	must	be	finely	tuned	to	limit	organ	damage	but	con‐
tain	bacterial	growth	and	spreading.	This	is	evidenced	by	the	ben‐
eficial	role	of	the	delayed	injection	of	DNase	in	cecal	ligation	and	
puncture	models	compared	to	the	detrimental	effect	observed	at	
an	earlier	time	in	sepsis.148
The	liver	has	specialized	macrophages,	known	as	Kupffer	cells,	
that	line	the	walls	of	the	sinusoids	and	are	thus	constantly	exposed	
to	the	blood	flow.	Under	physiological	conditions,	platelets	tran‐
siently	 interact	 with	 intravascular	 Kupffer	 cells	 via	 GPIbα‐VWF	
as	part	of	 the	 innate	 immune	surveillance	 system	of	 the	 liver.149 
The	 interaction	of	platelets	with	Kupffer	cells	 is	stabilized	 in	the	
presence	of	bacteria	such	as	Bacillus cereus	and	methicillin‐resis‐
tant Staphylococcus aureus	 through	 GPIIbIIIa‐mediated	 platelet	
adhesion.	 Platelet	 stable	 adhesion	 increases	 neutrophil	 recruit‐
ment	to	the	 liver	sinusoids	and	participates	 in	the	host	response	
against	the	pathogen.149	More	recently,	the	platelet	ITAM	recep‐
tors	CLEC‐2	and	GPVI	have	been	shown	to	regulate	platelet	inter‐
action	with	neutrophils	and	macrophages	during	 infection.3,83‒86 
GPVI	 promotes	 platelet‐neutrophil	 interaction	 during	 pneumo‐
nia	 increases	 host	 defense	 against	 pathogens.87 The interaction 
of	 podoplanin	 upregulated	 on	 inflammatory	 macrophages	 has	
been	shown	to	promote	CLEC‐2–mediated	platelet	aggregation	in	
vitro150 and in vivo.84	 In	 a	mouse	model	 of	 systemic	 Salmonella 
typhimurium	infection,	platelet	CLEC‐2	interacts	at	the	site	of	vas‐
cular	 breaches	with	 podoplanin‐positive	macrophages	 and	 drive	
pathogenic	thrombosis	 in	the	 liver.84	These	thrombi	did	not	con‐
tain Salmonella	 and	 peaked	when	 bacteria	 in	 the	 blood	 and	 tis‐
sues	were	 declining.	Deletion	 of	 platelet	 CLEC‐2	 abolished	 liver	
thrombosis	 without	 altering	 bacterial	 count.142	 In	 contrast,	 the	
CLEC‐2‐podoplanin	axis	inhibits	inflammation	in	mouse	models	of	
LPS‐induced	acute	 respiratory	distress	 syndrome	and	 cecal	 liga‐
tion	and	puncture	without	altering	thrombosis.83,85,86 The inhibi‐
tion	of	CLEC‐2–podoplanin	 interaction	exacerbates	 the	 cytokine	
storm	and	impairs	macrophages	recruitment	to	the	infected	peri‐
toneum	 increasing	 bacterial	 load.	 Therefore,	 the	 nature	 and	 re‐
ceptors	involved	in	PLAs	formation	in	sepsis	depends	on	the	organ	
involved,	the	time	course	of	the	infection,	and	the	insult.
PLAs	are	also	increased	in	septic	patients	and	exhibit	a	recip‐
rocal	relationship	to	survival	in	patients	developing	multiple	organ	
failure,	 probably	 due	 to	 an	 increase	 in	 sequestration.151	 Indeed,	
platelet‐neutrophil	 aggregates	 are	 elevated	 during	 the	 early	
phases	 of	 sepsis	 but	 significantly	 decrease	 with	 sepsis	 progres‐
sion.151	An	increase	in	platelet‐monocyte	aggregates	is	associated	
with	increased	mortality	in	older	septic	patients	but	not	in	younger	
patients.152	Therefore,	 targeting	platelet‐immune	cell	 interaction	
in	sepsis	plays	either	beneficial	or	detrimental	roles	according	to	
the	model,	disease	stage,	and	associated	comorbidities.	Similarly,	
the	 role	 of	 PLAs	depends	on	 the	 stage	of	 the	 infection,	 the	 im‐
mune	cells	involved,	and	their	contribution	to	pathogen	clearance,	
and	organ	damage.
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There	is	compelling	evidences	for	a	functional	relevance	of	plate‐
let‐leukocyte	 interactions	 in	 thrombo‐inflammatory	 diseases.	
Many	antiplatelet	drugs	or	 inhibitors	 targeting	 selective	 interac‐
tions	between	platelets	and	leukocytes	were	shown	to	modulate	
clinical	outcome	in	experimental	models.	The	protective	or	delete‐
rious	effect	of	 these	 interactions	on	the	clinical	outcome	 largely	
depends	on	the	pathophysiological	context	and	disease	stage.21,153 
This	 is	 not	 surprising	 based	on	 recent	 studies	 showing	 different	
thrombo‐inflammatory	 mechanisms	 in	 different	 organs	 and	 at	
different	 disease	 stages.	Moreover,	 the	 dynamic	 of	 platelet	 and	
leukocyte	engagement	in	the	arterial	and	venous	inflamed	vascu‐
latures	might	require	selective	inhibitors	for	successful	therapies	
in	different	diseases.	GPVI	 inhibitors	have	emerged	as	promising	
targets	to	reduce	thrombus	formation	on	atherosclerotic	plaques	
and	 possibly	 in	 other	 atherothrombotic	 diseases.111	 CLEC‐2	 is	 a	
potential	target	in	the	inflamed	venous	system	including	DVT	and	
Salmonella‐mediated	 thrombosis	 in	 the	 liver.	 However,	 the	 clini‐
cal	efficacy	 in	 thrombo‐inflammatory	disease	 in	human	 is	still	 to	
be	proven.	A	better	understanding	of	 the	dynamics	of	 thrombo‐
inflammatory	mechanisms	in	different	diseases	is	critical	for	suc‐
cessful	therapeutic	intervention	with	selective	inhibitors	required	
at	different	stage	of	the	disease	and	in	different	organs.
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